MedTrace Logo

Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer

NCT05035914 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2021-09-05

No results posted yet for this study

Summary

1. Determine the maximum tolerable dose (MTD) and / or phase II recommended dose (RP2D) of the allotinib combined mXELIRI protocol.
2. To evaluate the safety and tolerance of the combination of anlotinib and mXELIRI in the second-line treatment of patients with advanced colorectal cancer

Conditions

  • Advanced Colorectal Cancer

Interventions

DRUG

Anlotinib Hydrochloride

Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.

Sponsors & Collaborators

  • Guangdong Provincial Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Guangzhou University of Traditional Chinese Medicine

    lead OTHER

Principal Investigators

  • Haibo Zhang, Professor · Guangdong Provincial Hospital of Traditional Chinese Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-09
Primary Completion
2022-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05035914 on ClinicalTrials.gov